Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David A Sclar

Showing results (1-10 of 51) with videos related to

Pageof 6
Sort By:
Pharmacoeconomics|November 26, 2013
Use of proton pump inhibitors for the provision of stress ulcer prophylaxis: clinical and economic consequencesJeffrey F Barletta, David A Sclar
The Primary Care Companion for CNS Disorders|March 22, 2019
Quantifying Gabapentin Misuse With OpioidsAlyssa M Peckham, David A Sclar
The Journal of Clinical Psychiatry|September 7, 2012
Introduction: a fresh look at monoamine oxidase inhibitors for depressionLawrence J Cohen, David A Sclar
Pharmacoeconomics|October 13, 2010
Economic implications of sleep disordersTracy L Skaer, David A Sclar
Critical Care (London, England)|December 26, 2014
Proton pump inhibitors increase the risk for hospital-acquired Clostridium difficile infection in critically ill patientsJeffrey F Barletta, David A Sclar
The Journal of Clinical Psychiatry|September 7, 2012
Issues in adherence to treatment with monoamine oxidase inhibitors and the rate of treatment failureLawrence J Cohen, David A Sclar
Annals of Internal Medicine|June 18, 2019
Combined Gabapentinoid and Opioid UseAlyssa M Peckham, David A Sclar
Primary Care Companion to the Journal of Clinical Psychiatry|August 10, 2010
Hospital admission for schizophrenia and discharge against medical advice in the United StatesDavid A Sclar, Linda M Robison
The American Journal of Medicine|January 4, 2014
Anaphylaxis: underdiagnosed, underreported, and undertreatedDavid A Sclar, Phillip L Lieberman
The Journal of Clinical Psychiatry|February 20, 2013
MAOIs: issues in treatment adherence and rates of treatment failureLawrence J Cohen, David A Sclar
Pageof 6

Showing results (1-10 of 51) with videos related to

Sort By:
Pageof 6
Pharmacoeconomics|November 26, 2013
Use of proton pump inhibitors for the provision of stress ulcer prophylaxis: clinical and economic consequencesJeffrey F Barletta, David A Sclar
The Primary Care Companion for CNS Disorders|March 22, 2019
Quantifying Gabapentin Misuse With OpioidsAlyssa M Peckham, David A Sclar
The Journal of Clinical Psychiatry|September 7, 2012
Introduction: a fresh look at monoamine oxidase inhibitors for depressionLawrence J Cohen, David A Sclar
Pharmacoeconomics|October 13, 2010
Economic implications of sleep disordersTracy L Skaer, David A Sclar
Critical Care (London, England)|December 26, 2014
Proton pump inhibitors increase the risk for hospital-acquired Clostridium difficile infection in critically ill patientsJeffrey F Barletta, David A Sclar
The Journal of Clinical Psychiatry|September 7, 2012
Issues in adherence to treatment with monoamine oxidase inhibitors and the rate of treatment failureLawrence J Cohen, David A Sclar
Annals of Internal Medicine|June 18, 2019
Combined Gabapentinoid and Opioid UseAlyssa M Peckham, David A Sclar
Primary Care Companion to the Journal of Clinical Psychiatry|August 10, 2010
Hospital admission for schizophrenia and discharge against medical advice in the United StatesDavid A Sclar, Linda M Robison
The American Journal of Medicine|January 4, 2014
Anaphylaxis: underdiagnosed, underreported, and undertreatedDavid A Sclar, Phillip L Lieberman
The Journal of Clinical Psychiatry|February 20, 2013
MAOIs: issues in treatment adherence and rates of treatment failureLawrence J Cohen, David A Sclar
Pageof 6